1
|
Chhieng DC, Cangiarella JF, Symmans WF, Cohen JM. Fine-needle aspiration cytology of Hodgkin disease: a study of 89 cases with emphasis on false-negative cases. Cancer 2001; 93:52-9. [PMID: 11241266 DOI: 10.1002/1097-0142(20010225)93:1<52::aid-cncr9007>3.0.co;2-3] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED INTRODUCTION. Although the cytologic features of Hodgkin disease (HD) has been well described, HD accounts for most of the false-negative fine-needle aspiration (FNA) biopsies of malignant lymphomas. In this study, the authors examined the factors contributing to a false-negative diagnosis of HD. METHODS Eighty-nine cases from 72 patients (23 females and 49 males) with HD evaluated by FNA were identified between 1990 and 1999. The patients' ages ranged from 5 to 90 years (median, 38 years). Eighty-five FNAs were from lymph nodes, and 4 were from extranodal sites. Histologic correlation was available for all patients. RESULTS Based on the original cytologic diagnosis, 43 (48.3%) cases had a positive diagnosis of HD, 20 (22.5%) suspicious or atypical diagnosis, 13 (14.6%) a benign diagnosis (false-negative cases), and 10 (11.2%) were nondiagnostic. Three (3.4%) additional cases had a malignant diagnosis other than HD. After review, three false-negative cases were reclassified as HD and seven as atypical lymphoid proliferation. Three of these 10 cases also showed conspicuous collections of histiocytes mimicking poorly formed granulomas. In those "atypical" cases, only rare Reed-Sternberg (R-S) cells variants were identified. No R-S cells or its variants were identified in the remaining three false-negative cases; subsequent excisional biopsy showed partial involvement of the lymph node by HD in two cases. Among the nondiagnostic cases, nine cases showed considerable fibrosis in the resected lymph node. In addition, six cases were performed without on-site assessment. CONCLUSIONS The cytologic diagnosis of HD can be challenging when classic R-S cells are absent. Contributing factors for a false-negative diagnosis include obscuring reactive inflammatory cells, fibrosis of the involved lymph nodes, partial involvement of the lymph node by HD, sampling error, and misinterpretation. On-site assessment significantly minimizes the false-negative diagnostic rate. Furthermore, additional material can be obtained for ancillary studies. Cancer (Cancer Cytopathol)
Collapse
Affiliation(s)
- D C Chhieng
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35249-6823, USA.
| | | | | | | |
Collapse
|
2
|
Eghbali H, Soubeyran P, Tchen N, de Mascarel I, Soubeyran I, Richaud P. Current treatment of Hodgkin's disease. Crit Rev Oncol Hematol 2000; 35:49-73. [PMID: 10863151 DOI: 10.1016/s1040-8428(99)00070-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
In spite of the fact that Hodgkin's disease (HD) remains still an enigma its management and treatment yield a cure rate of about 80% of all patients. However, this management has two limits: on one side favourable cases which should not be overtreated because of unacceptable side-effects, and on the other side very unfavourable cases which should be treated differently because of a very high rate of failure and/or relapse. Then it becomes necessary to precise as thoroughly as possible these two limits in order to choose the adequate treatment for the patient. Prognostic factors based on patient and disease characteristics allow a relatively exact classification of favourable and unfavourable cases. This distinction in two prognostic groups has therapeutic implications in terms of chemotherapy (regimen, duration) and radiotherapy (extension, doses). Other specific situations have to be considered, e.g. pediatric cases, pregnancy, old age and HIV-infected patients who need an adapted management according to very different situations.
Collapse
Affiliation(s)
- H Eghbali
- Institut Bergonié, Regional Cancer Centre, 180, rue de Saint-Genès, F-33076 Cedex, Bordeaux, France.
| | | | | | | | | | | |
Collapse
|
3
|
Franklin J, Tesch H, Hansmann ML, Diehl V. Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Ann Oncol 1999; 9 Suppl 5:S39-44. [PMID: 9926236 DOI: 10.1093/annonc/9.suppl_5.s39] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The special nature and course of lymphocyte rich variants of Hodgkin's disease (HD) has been the subject of pathological and clinical studies since the 1930s. Patients with lymphocyte predominant (LP) HD, predominantly male and 25-45 years old, usually present with early clinical stage, cervical or inguinal involvement and few if any adverse prognostic factors. The disease progresses slowly, with fairly frequent relapses which are rarely fatal. Nonetheless, cases with advanced stage and deaths from Hodgkin's disease have been observed in LPHD. Recently, immunological studies have lead to a clear distinction between LPHD and classical HD including a lymphocyte rich classical version (LRCHD). Secondary low-grade NHLs occur more frequently after LPHD than after classical HD. They seem to be disease-related rather than treatment-induced. LPHD patients in earlier studies have tended to have a better prognosis than classical HD patients. When cohorts of the same clinical stage are compared, under modern protocol treatment this advantage seems to be minimal or absent. LPHD patients tend to relapse frequently but they survive these relapses better than classical HD patients. The resemblance to non-neoplastic disorders, capability for ongoing mutation, favorable clinical presentation and good survival rates after relapse all suggest that the optimal primary treatment strategy might be less intensive for LPHD than for classical HD. Late toxicities, which contribute considerably to the death rate, could thus be reduced. The long survival of several early stage LPHD patients without any treatment beyond lymph node excision could favour a 'watch-and-wait' strategy, albeit only after rigorous staging. New experimental therapy techniques such as immunotherapy might also be suitable. These possibilities must first be tested in a large-scale prospective study.
Collapse
Affiliation(s)
- J Franklin
- Department of Internal Medicine, University of Cologne, Germany.
| | | | | | | |
Collapse
|
4
|
Klapper SR, Jordan DR, McLeish W, Pelletier C. Unilateral proptosis in an immunocompetent man as the initial clinical manifestation of systemic Hodgkin disease. Ophthalmology 1999; 106:338-41. [PMID: 9951487 DOI: 10.1016/s0161-6420(99)90073-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
OBJECTIVE Orbital involvement in Hodgkin disease (HD) is rare. Previously reported cases of HD in patients without the acquired immunodeficiency syndrome have been diagnosed late in the course of established systemic disease. The authors describe an immunocompetent man with orbital infiltration as the initial manifestation of systemic HD. DESIGN Case report. PARTICIPANTS A 47-year-old man with acute progressive, painless proptosis of the left eye is described. INTERVENTION A well-defined, homogeneous soft tissue mass of the superior left orbit was evident on computed tomography, and an incisional biopsy of the nontender mass was performed. RESULTS The histopathologic findings were characteristic of HD. Systemic investigations showed clinical stage 3A HD. Ten months after completion of hybrid chemotherapy, the patient remained in complete remission from his HD. CONCLUSION Hodgkin disease presenting initially in the orbit of a patient with the acquired immunodeficiency syndrome has been described previously. The patient presented in this report is the first case of HD in the recent English literature with the initial manifestation in the orbit of an otherwise immunocompetent patient.
Collapse
Affiliation(s)
- S R Klapper
- University of Ottawa Eye Institute, Ontario, Canada
| | | | | | | |
Collapse
|
5
|
Baur AS, Meugé-Moraw C, Michel G, Delacrétaz F. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998; 32:512-20. [PMID: 9675590 DOI: 10.1046/j.1365-2559.1998.t01-1-00418.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIMS In nodular sclerosing Hodgkin's disease (NSHD), the prognostic relevance of the histopathological grading in two subtypes NSI (low-grade) and NSII (high-grade) remains controversial. Analysis of follicular dendritic cells (FDC) may provide new prognostic parameters. METHODS AND RESULTS Tumours from 59 patients with NSHD were studied. Mean follow-up time was 8 years. Forty-one cases were classified as NSI and 18 as NSII. FDC were immunostained with the paraffin-resistant monoclonal antibodies CD21 and CNA.42. We distinguished three patterns in the neoplastic tissue: FDC1, the presence of well-defined follicle-like structures (n = 20); FDC2, the presence of largely destroyed FDC networks (n = 25); and FDC3, no or a few isolated FDC (n = 14). The three groups differed clearly regarding the frequency of relapse and the survival. The longest survival was seen in the FDC1 group, the shortest in the FDC3 group, the FDC2 group being intermediate (P = 0.0025). FDC status was a discriminating prognostic factor for all patients, and within various age and stage categories. Combining the FDC status and the NSI-NSII grading defined the best survival group as FDC1-NSI. CONCLUSIONS Assessment of FDC pattern, associated with histological subtyping, brings valuable data for predicting survival and outcome in NSHD.
Collapse
Affiliation(s)
- A S Baur
- Institut Universitaire de Pathologie, Lausanne, Switzerland
| | | | | | | |
Collapse
|
6
|
Diebold J, Jungman P, Molina T, Audouin J. Recent advances in Hodgkin's disease: an overview and review of the literature. ACTA ACUST UNITED AC 1995. [DOI: 10.1016/s0968-6053(05)80054-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Damotte D, Le Tourneau A, Audouin J, Duval C, Martin-Bastenaire F, Villain O, Delobelle-Deroide A, Diebold J. Discordant malignant lymphoma synchronous or successive high-grade B lymphoma associated with Hodgkin's disease. A clinico pathologic and immunophenotypic study of 4 cases. Pathol Res Pract 1995; 191:8-15. [PMID: 7651937 DOI: 10.1016/s0344-0338(11)80916-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We report in 4 patients the rare association of Hodgkin's disease and high grade B malignant lymphoma. In 2 cases, both tumours were disclosed at the same time but in different tissues from the same region. In the 2 other patients, the second tumour was found 11 months and 12 months after the first respectively. In all cases Hodgkin's disease was of the nodular sclerosing type, the tumour cells expressing CD 30 and CD 15. The high grade lymphomas were of the polymorphic centroblastic (large non cleaved) type and expressed the B markers. One (case 4) was secondary to a follicular lymphoma. In 2 cases (2 and 4) the search for a latent EBV infection was negative in both tumours. In case 1, only the Reed-Sternberg cells were positive with both techniques. Such an association is different from so-called composite lymphomas, and can be called "discordant lymphoma". Different related conditions are discussed. This association is distinct from lymphomas or Hodgkin's disease complicating the treatment of Hodgkin's disease or malignant lymphomas.
Collapse
Affiliation(s)
- D Damotte
- Service Central Jacques-Delarue d'Anatomie et de Cytologie Pathologiques, Hotel-Dieu, France
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments? Leuk Lymphoma 1995; 15 Suppl 1:31-40. [PMID: 7767258 DOI: 10.3109/10428199509052703] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Death remains a common event in patients with advanced stage Hodgkin's disease (HD) and also occurs in early stages. Identification of the population of HD patients who would best benefit from an intensification of the treatment is therefore necessary in both cases. A comparative review of prognostic criteria must be attempted through recent randomized trials using conventional treatment, independently of criteria used by the autologous bone-marrow transplant (ABMT) teams which rather aim to select relapsing patients. When freedom from progression (FFP) is considered in recent large series, the factors which most often predict for a high risk of failure are bulky mediastinum, B symptoms, stage in advanced HD and the number of nodal areas in early HD. However, prognostic data available to date cannot sort out any group of patients that would clearly require a high dose/potentially risky therapy. Because of the failure to identify consensual prognostic factors, the population considered till now for upfront intensification is restricted to a very small subgroup of patients with advanced disease (< to 5% of them), which makes the conduct of randomized trials very difficult within reasonable delays. The potential to identify and to clear part of the difficulties encountered with the prognostic analysis depends on the population studied: size of the data base, follow-up, disease stages, treatments given, outcome criteria selected. Finally, "sorted out" new patients with advanced and perhaps early stage HD may benefit from treatment intensification. As the initial selection characteristics are still poorly defined, a proposition is made to collect, eventually through the International Data Base for Hodgkin's Disease (IDHD) pertinent recent trials and to launch a survey. The results of the survey will be discussed at the Third International Symposium on Hodgkin's lymphoma in Köln (21-23 September 1995). Hazards of intensified regimens may be better quantified by then, so that newer more efficient strategies may be designed.
Collapse
Affiliation(s)
- P Carde
- Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
9
|
Abstract
This article reviews geriatric oncology and assesses options for treatment and care of the elderly patient with cancer. The size of the population over 65 years old is defined, with particular reference to the continuing growth of this subsection of the community. The high incidence of many cancers and their associated mortality rates in the elderly are identified and the epidemiology of such diseases in the geriatric population is addressed. Given the discrepancies in incidence and survival rates between patients younger and older than 65 years, the association between tumorigenesis and the aging process is explored. Specific aspects of tumor growth in the elderly are considered. General considerations of therapy for elderly patients with cancer are discussed, including the pharmacokinetics and pharmacodynamics of chemotherapy in those over 65 years old, surgical options, the use of radiotherapy, and overall patient assessment. Next, treatment options for individual cancer states are reviewed, with particular emphasis on newer treatment options designed specifically for the elderly. Sections on cancer screening and supportive care are also included, the latter dealing with aspects of symptom control, quality of life assessment, and the physical and psychologic rehabilitation of the elderly patient with cancer who is undergoing treatment. Conclusions are then drawn as to the extent of the oncological process in those over 65 years old, with particular emphasis on the underdiagnosis and undertreatment of many malignancies in the past. The challenge created by the growing elderly population is underscored and necessary plans of action for oncologists in the future are defined. Such proposals are necessary if inroads are to be made into the unacceptable morbidity and mortality rates borne by our elderly patients with cancer.
Collapse
Affiliation(s)
- A Byrne
- Department of Medical Oncology, Mater Misericordiae Hospital Dublin, Ireland
| | | |
Collapse
|
10
|
Mir R, Anderson J, Strauchen J, Nissen NI, Cooper MR, Rafla S, Canellos GP, Bloomfield CD, Gottlieb AJ, Peterson B. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer 1993; 71:1857-66. [PMID: 8448750 DOI: 10.1002/1097-0142(19930301)71:5<1857::aid-cncr2820710524>3.0.co;2-b] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
BACKGROUND This article reviews the salient pathologic and clinical features of 171 patients with Stage III-IV disease who were 60 years of age or older who were treated on four Hodgkin disease (HD) protocols from 1969 to 1988. METHODS Pretherapy sections were reviewed centrally for correlation of the histologic classification with anatomic sites of involvement and survival. RESULTS The diagnosis of HD was confirmed in 114 (66.7%) patients. Non-Hodgkin lymphomas (NHL) and a miscellaneous non-HD group accounted for 52 (30.4%) and 5 (2.9%) of the cases. The overall median survival times of patients with Stage III-IV HD and NHL who were 60 years of age or older in the four protocols were not significantly different (1.5 versus 1.3 years, respectively; P = 0.28). There also was no significant correlation between the survival of these patients with HD and either the Rye classification, 19 specific histologic parameters, or the British National Lymphoma Investigation grading system for HDNS. In the last protocol, the 5-year survival rate of patients with HD who were 60 years of age or older was lower than that of patients 40-59 years of age or that of those younger than 40 years of age (31% versus 63% versus 79%, respectively, P < 0.0001). Patients with HD entered into the two most recent protocols showed lower incidences of involvement of cervical and iliac-inguinal-femoral lymph nodes and skin-subcutaneous tissues than the patients with NHL who were misdiagnosed as HD. Moreover, patients with Stage III-IV HD in the most recent protocol who were 60 years of age or older had lower rates of involvement of the cervical and mediastinal-hilar lymph nodes and a higher rate of involvement of the gastrointestinal tract than younger patients. CONCLUSIONS Patients with Stage III-IV HD and NHL who are 60 years of age or older differ with respect to the rates of involvement of specific anatomic sites but not in survival when treated with HD protocols. In contrast, patients of different age groups with Stage III-IV HD disease differ with regard to the rates of involvement of anatomic sites and survival.
Collapse
Affiliation(s)
- R Mir
- Long Island Jewish Medical Center, New Hyde Park, New York
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Carde P. Hodgkin's disease--I: Identification and classification. BMJ (CLINICAL RESEARCH ED.) 1992; 305:99-102. [PMID: 1638255 PMCID: PMC1882623 DOI: 10.1136/bmj.305.6845.99] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- P Carde
- Service de Médecine C S Axel Unit, Institut Gustave-Roussy, Villejuif, France
| |
Collapse
|
12
|
Affiliation(s)
- W J Urba
- Clinical Immunology Services, Program Resources, Inc./DynCorp, Frederick, Md
| | | |
Collapse
|
13
|
MacLennan KA, Bennett MH, Vaughan Hudson B, Vaughan Hudson G. Diagnosis and grading of nodular sclerosing Hodgkin's disease: a study of 2190 patients. INTERNATIONAL REVIEW OF EXPERIMENTAL PATHOLOGY 1992; 33:27-51. [PMID: 1733871 DOI: 10.1016/b978-0-12-364933-1.50007-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- K A MacLennan
- Department of Pathology, Royal Marsden Hospital, London, England
| | | | | | | |
Collapse
|
14
|
Affiliation(s)
- L Specht
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|